UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.

Pyxis Oncology, a US-based cancer therapy developer spun out of University of Chicago (UChicago), set the price range for its proposed IPO at $14 to $16 yesterday. The spinout plans to issue 8.34 million shares on the Nasdaq Global Market to list under the ticker symbol PYXS. At the lower end, Pyxis would generate nearly…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.